Valuation: Waverley Pharma Inc.

Market Cap 540K 378K 340K 317K 288K 35.99M 543K 3.81M 1.49M 18.68M 1.42M 1.39M 60.08M P/E 2024
-0.57x
P/E 2025 -2.16x
Enterprise Value 3.94M 2.76M 2.48M 2.32M 2.1M 263M 3.96M 27.78M 10.85M 136M 10.36M 10.13M 438M EV / Sales 2024
7.09x
EV / Sales 2025 3.32x
Free-Float
25.1%
Yield 2024 *
-
Yield 2025 -
1 month-33.33%
3 months-60.00%
Current year-50.00%
1 week 0.01
Extreme 0.01
0.01
1 month 0.01
Extreme 0.01
0.02
Current year 0.01
Extreme 0.01
0.04
1 year 0.01
Extreme 0.01
0.04
3 years 0.01
Extreme 0.01
0.04
5 years 0.01
Extreme 0.01
0.12
10 years 0.01
Extreme 0.01
0.6
Manager TitleAgeSince
Chief Executive Officer - 2020-01-31
Director of Finance/CFO - 2019-12-31
Director TitleAgeSince
Chairman 79 2016-12-13
Director/Board Member 54 2016-12-13
Director/Board Member - 2023-11-21
Date Insider Type Main position Quantity % Market Cap. Importance
8/16/26 Option

Chairman

-10,000,000 18.5185%
6/24/24 Other

Director

0 0%
8/18/21 Other

Chairman

0 0%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00%-60.00%-71.43% 378K
-2.01%-7.86%+60.74%+70.97% 68.92B
+3.84%-11.02%+8.59%+57.43% 51.9B
+3.35%+1.42%+11.85%+40.01% 48.73B
+0.51%+1.51%+27.96%+31.43% 43.13B
+2.70%-3.66%+307.41%+547.01% 41.48B
+0.69%-3.44%+9.52%+96.59% 39.96B
+0.06%-2.02%+11.25%+43.27% 30.6B
-0.56%-8.58%+37.62%+0.94% 26.01B
-0.39%-6.92%-13.60%-14.40% 22.27B
Average +0.82%-4.60%+40.13%+80.18% 37.3B
Weighted average by Cap. +0.98%-4.89%+55.14%+103.90%

Financials

2024 2025
Net sales 475K 333K 299K 279K 253K 31.69M 478K 3.35M 1.31M 16.44M 1.25M 1.22M 52.89M 1.35M 945K 850K 793K 719K 89.96M 1.36M 9.52M 3.72M 46.69M 3.55M 3.47M 150M
Net income -947K -663K -596K -557K -504K -63.13M -953K -6.68M -2.61M -32.76M -2.49M -2.44M -105M -499K -350K -314K -293K -266K -33.27M -502K -3.52M -1.37M -17.27M -1.31M -1.28M -55.54M
Net Debt 2.83M 1.98M 1.78M 1.66M 1.51M 189M 2.85M 19.96M 7.79M 97.92M 7.44M 7.28M 315M 3.4M 2.38M 2.14M 2M 1.81M 227M 3.42M 23.98M 9.36M 118M 8.94M 8.75M 378M
Projected Income Statement - Annual - Waverley Pharma Inc.
Logo Waverley Pharma Inc.
Waverley Pharma Inc. is a biopharmaceutical company engaged in the research, development and commercialization of human therapeutics focused on oncology. It is advancing its PARP-1 pre-clinical development program, which is in the lead optimization stage, in response to the interest in novel PARP-1 inhibitors that demonstrate selective activity against PARP-1 over PARP-2. The lead compound exhibits single-digit nanomolar activity and significant selectivity for PARP-1 over PARP-2, in pre-clinical invitro testing. It has entered into a license, manufacture, supply, marketing and distribution agreement with Reliance Life Sciences Private Limited (Licensor or RLS) by which the Licensor granted the Company an exclusive territorial license to market and sell capecitabine in the United Kingdom (UK) and Germany as well as a non-exclusive territorial license to market and sell temozolomide in the UK. It also has territorial licenses from RLS to two oncologic drugs, pemetrexed and bortezomib.
Employees
-
Date Price Change Volume
26-10-09 CA$0.0100 0.00% 2,000
26-10-08 CA$0.0100 0.00% 2,000
  1. Stock Market
  2. Stocks
  3. WAVE Stock